Broadview Ventures leads €5M financing for breakthrough therapy for intracranial haemorrhage

Broadview Ventures leads €5M financing for breakthrough therapy for intracranial haemorrhage

Alveron Pharma, based in the Netherlands and UK,  is pleased to announce a €5.0 million Series Seed extension financing to advance the development of its innovative drug, OKL-1111, for the treatment of intracranial haemorrhage (ICH). The syndicate is led by Broadview Ventures and includes the participation of all existing investors including Sanquin (the Dutch Blood Foundation), Thuja Capital, Waterman Ventures and Oost NL.  Alveron Pharma is developing a synthetic anticoagulant and platelet inhibitor reversal agent to prevent haematoma expansion and improve clinical outcomes in patients with ICH. Current therapies for treating ICH patients on anticoagulants have cumbersome regimens, resulting in excessive door to needle times, often exceeding two hours, which exacerbate poor outcomes for these patients. OKL-1111 has a universal mode of action by binding to a downstream clotting factor and a unique product profile enabling administration within 10 minutes of a diagnosing CT scan. In addition, the drug reverses the effects of clopidogrel, a major platelet inhibitor, for which there is currently no antidote. The capital provided from this new financing enables Alveron to accelerate important development activities that support OKL-1111´s readiness for further clinical studies to demonstrate safety and proof-of-concept efficacy in patients.

For more information please contact:

Ben Nichols   ben.nichols@alveron.com

Benjamin Kreitman  bkreitman@broadviewventures.org

Michel  Briejer   Michel Briejer <michel.briejer@thujacapital.com